Track Bionano Genomics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Bionano Genomics, Inc. BNGO · Stock Open Bionano Genomics, Inc. in new tab

1.00 USD
P/E
0.04
EPS
-2.90
P/B
0.48
ROE
-77.20
Beta
1.71
Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

🧾 Earnings Recap – Q1 2026

Bionano’s shares fell 0.8% after earnings, reflecting investor caution despite modest growth in consumable revenues and improved reimbursement codes; softness in software revenue and ongoing execution risks likely weighed on sentiment.

  • Q1 2026 flow cell sales reached a record 8,178 units, up 17% year-over-year, with flow cells sold to existing customers up 21% YoY.
  • Consumable revenue grew 20% year-over-year to $3.9 million, signaling traction in routine users and OGM focus.
  • Software revenue declined sharply by 40% year-over-year to $1.2 million due to a large prior-year sale that supplied customers through 2026.
  • Other revenue increased 36% year-over-year to $1.6 million, reflecting a higher proportion of recurring revenues.
  • Two significant reimbursement milestones took effect, increasing payment rates for key CPT codes by up to 47%, potentially improving long-term adoption economics.
📅
Loading chart...
Key Metrics
Earnings dateMarch 22, 2027
P/E0.04
EPS-2.90
Book Value2.09
Price to Book0.48
Debt/Equity23.19
% Insiders2.425%
Growth
Revenue Growth0.12%
Estimates
Forward P/E-1.03
Forward EPS-0.97

DCF valuation

Model fair value for Bionano Genomics, Inc. (BNGO)
Result
Sign in to run the valuation for BNGO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Bionano Genomics, Inc. Logo Bionano Genomics, Inc. Analysis (BNGO)

United States Health Care Official Website Stock

Is Bionano Genomics, Inc. a good investment? Bionano Genomics, Inc. (BNGO) is currently trading at 1.00 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.04. This relatively low multiple may signal that Bionano Genomics, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Bionano Genomics, Inc. is expected to release its next earnings report on March 22, 2027. The market consensus estimate for Forward EPS is -0.97.

Investor FAQ

Does Bionano Genomics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Bionano Genomics, Inc.?

Bionano Genomics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 22, 2027. The company currently has a trailing EPS of -2.90.

Company Profile

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Exchange Ticker
NCM (Australia) BNGO
US09075F1075
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 7, 2023 1:10
Jan. 27, 2025 1:60
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion